Green Stock News Green Stock News

LEXARIA BIOSCIENCE NASDAQLEXX STOCK QUOTE

https://www.lexariabioscience.com/

LATEST NEWS FROM LEXARIA BIOSCIENCE

October 13, 2021
Lexaria's Technology Proven to Deliver Oral THC More Effectively
October 12, 2021
IBN Announces Latest Episode of Stock2Me Podcast Featuring Lexaria Bioscience Corp. Chairman & CEO Chris Bunka
October 5, 2021
DehydraTECH(TM) Nicotine Pouches Could Make Smoking Obsolete
October 5, 2021
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
September 9, 2021
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 8, 2021
Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
September 7, 2021
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
August 17, 2021
Winning Formulation; Lexaria Takes Strategic Aim at High Value Hypertension and Antiviral Therapeutics Markets with Robust Drug Delivery Technology
July 29, 2021
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
July 28, 2021
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
July 27, 2021
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
July 26, 2021
Lexaria Receives US$3,817,643 From Warrant Exercises
July 22, 2021
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
July 21, 2021
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
July 15, 2021
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
July 13, 2021
Lexaria Receives Patent Protection in Japan
July 5, 2021
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
June 29, 2021
Lexaria Announces 2021 Annual Meeting Results
June 21, 2021
Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021
June 17, 2021
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
June 15, 2021
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
June 9, 2021
Lexaria Provides Progress Report on Six R&D Programs
June 7, 2021
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
June 3, 2021
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
May 20, 2021
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
May 12, 2021
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
March 16, 2021
Lexaria's Antiviral Drug Evaluation Program Progressing
March 15, 2021
Rapid Progress in Hypertension Studies by Lexaria
March 11, 2021
Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021
February 16, 2021
Lexaria Enters Investor Relations Agreement
February 11, 2021
Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies